Market Research Logo

Innate Pharma SA - Product Pipeline Review - 2015

Innate Pharma SA - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Innate Pharma SA - Product Pipeline Review - 2015’, provides an overview of the Innate Pharma SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Innate Pharma SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Innate Pharma SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Innate Pharma SA’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Innate Pharma SA’s pipeline products
Reasons to buy
  • Evaluate Innate Pharma SA’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Innate Pharma SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Innate Pharma SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Innate Pharma SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Innate Pharma SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Innate Pharma SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Innate Pharma SA Snapshot
Innate Pharma SA Overview
Key Information
Key Facts
Innate Pharma SA - Research and Development Overview
Key Therapeutic Areas
Innate Pharma SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Innate Pharma SA - Pipeline Products Glance
Innate Pharma SA - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Innate Pharma SA - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Innate Pharma SA - Drug Profiles
IPH-2201
Product Description
Mechanism of Action
R&D Progress
IPH-33
Product Description
Mechanism of Action
R&D Progress
IPH-4102
Product Description
Mechanism of Action
R&D Progress
IPH-43
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Cancer and Inflammation
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 1 for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 2 for Cancer
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit NKp46 for Cancer and Inflammation
Product Description
Mechanism of Action
R&D Progress
Innate Pharma SA - Pipeline Analysis
Innate Pharma SA - Pipeline Products by Target
Innate Pharma SA - Pipeline Products by Route of Administration
Innate Pharma SA - Pipeline Products by Molecule Type
Innate Pharma SA - Pipeline Products by Mechanism of Action
Innate Pharma SA - Recent Pipeline Updates
Innate Pharma SA - Dormant Projects
Innate Pharma SA - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Autologous Gamma Delta T Lymphocytes
IPH-1101
IPH-1201
IPH-2101
IPH-3102
IPH-3201
IPH-4101
IPH-4201
Innate Pharma SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Innate Pharma SA, Key Information
Innate Pharma SA, Key Facts
Innate Pharma SA - Pipeline by Indication, 2015
Innate Pharma SA - Pipeline by Stage of Development, 2015
Innate Pharma SA - Monotherapy Products in Pipeline, 2015
Innate Pharma SA - Out-Licensed Products in Pipeline, 2015
Innate Pharma SA - Out-Licensed Products/ Combination Treatment Modalities, 2015
Innate Pharma SA - Phase II, 2015
Innate Pharma SA - Phase I, 2015
Innate Pharma SA - Preclinical, 2015
Innate Pharma SA - Discovery, 2015
Innate Pharma SA - Pipeline by Target, 2015
Innate Pharma SA - Pipeline by Route of Administration, 2015
Innate Pharma SA - Pipeline by Molecule Type, 2015
Innate Pharma SA - Pipeline Products by Mechanism of Action, 2015
Innate Pharma SA - Recent Pipeline Updates, 2015
Innate Pharma SA - Dormant Developmental Projects,2015
Innate Pharma SA - Discontinued Pipeline Products, 2015
Innate Pharma SA, Subsidiaries
List of Figures
Innate Pharma SA - Pipeline by Top 10 Indication, 2015
Innate Pharma SA - Pipeline by Stage of Development, 2015
Innate Pharma SA - Monotherapy Products in Pipeline, 2015
Innate Pharma SA - Out-Licensed Products in Pipeline, 2015
Innate Pharma SA - Pipeline by Top 10 Target, 2015
Innate Pharma SA - Pipeline by Top 10 Route of Administration, 2015
Innate Pharma SA - Pipeline by Top 10 Molecule Type, 2015
Innate Pharma SA - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report